Form 4: Amgen CEO Robert Bradway Reports Stock Transactions

Amgen's CEO, Robert Bradway, reports the disposition of shares to cover tax obligations and holdings through GRATs.

Summary

• Robert A. Bradway, CEO, Chairman, and President of Amgen Inc., filed a Form 4 detailing changes in beneficial ownership of Amgen stock.
• On April 30, 2025, Bradway disposed of 2,544 shares of common stock at a price of $288.56 per share to cover tax obligations.
• Following the transaction, Bradway directly owns 405,021 shares of Amgen common stock.
• Bradway also indirectly owns 90,000 shares through a Grantor Retained Annuity Trust (GRAT) and another 90,000 shares through a spousal GRAT.
• The directly held shares include 2,169 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Amgen, Bradway, Stock Transaction, Grat, Dividend Equivalents